Biograil Forms International Scientific Advisory Board with Diverse Expertise to Support Further Optimization of the proprietary BIONDDTM Technology
COPENHAGEN, DENMARK, March 1st, 2022 – Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of biologics that would otherwise be injected, announced the formation of an expert scientific advisory board to support further optimization of the proprietary BIONDDTM technology. After achieving proof of concept of BIONDDTM Technology in a pre-clinical model the company is looking to further refine and diversify the platform to be used for various biological molecules and will use the SAB to support this process.
The Biograil SAB members are:
- David Brayden, Professor at University College Dublin, Ireland
- Ester Caffarel-Salvador, Science and Business Development Consultant and Lecturer at MIT, MA, United States
- Claus-Michael Lehr, Professor at Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Saarland University Saarbrücken, Germany
- Philip Just Larsen, SVP Global Head of Research, Bayer Pharmaceuticals, Germany
Biograil CEO Karsten Lindhardt said: “Biograil is very proud to announce support from such a highly experienced group of scientific leaders forming our SAB. We have also already experienced that the variety and complimentary expertise the group can provide can be of great future value for the company. We will use input from this amazing group of scientists to help us find the best possible technical and portfolio solutions for progressing our BIONDDTM platform technology”.
Science and Business Development Consultant and Lecturer at MIT, Ester Caffarel-Salvador, who is now a member of the Biograil Scientific Advisory Board, commented:
“I am very excited to be part of the Biograil SAB joining great colleagues who are experts in the field. I have worked for the last several years with oral delivery device systems and there is a lot of potential in the oral drug delivery space, so I am excited to see the progression of BIONDDTM technology. I look forward to sharing my experience in support of Biograil’s journey to benefit future patients by providing an alternative to injections for a more convenient route of drug delivery.”
Biograil will continue to develop the SAB according to current needs and plans to involve the SAB members in model development and research activities where appropriate. Biograil will also look for opportunities for non-dilutive funding of research activities with our research partners.
About Biograil Aps
Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device uses a proprietary mechanism to facilitate the delivery of active substances, i.e., biologics efficiently into the gastrointestinal wall. The team behind Biograil is a combination of seasoned entrepreneurs with long experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet approved by the FDA.